SCHEMBL5453077

SCHEMBL5453077

COc1ccc(CCl)cc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 2/20 0.59
CFD P00746 1/20 0.53
TTR P02766 2/20 0.51
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 2/20 0.49
HPGD P15428 2/20 0.49
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47
LDHA P00338 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
APP P05067 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31252031 1.00 MRGPRX4 (0.59) MRGPRX4CFDTTRALDH1A1KDM4E
SCHEMBL7645124 0.86 TTR (0.47) MRGPRX4TTRALDH1A1KDM4EHPGD
SCHEMBL31252078 0.86 TTR (0.47) MRGPRX4TTRALDH1A1KDM4EHPGD
SCHEMBL6866159 0.86 CFD (0.70) MRGPRX4CFDALDH1A1KDM4EHPGD
SCHEMBL4159034 0.85 HPGD (0.58) MRGPRX4TTRALDH1A1KDM4EHPGD
SCHEMBL31252170 0.85 LMNA (0.47) MRGPRX4TTRALDH1A1KDM4EHPGD
SCHEMBL31371151 0.85 HPGD (0.58) MRGPRX4TTRALDH1A1KDM4EHPGD
SCHEMBL384685 0.84 MRGPRX4 (0.57) MRGPRX4CFDALDH1A1KDM4EHPGD
SCHEMBL12837926 0.84 MRGPRX4 (0.57) MRGPRX4CFDALDH1A1KDM4EHPGD
SCHEMBL7597341 0.84 MRGPRX4 (0.57) MRGPRX4CFDALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4486453-A1 BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2025-01-08 EP disclosed
WO-2023166103-A1 BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. HOFFMANN-LA ROCHE AG (CH) 2023-09-07 WO disclosed
EP-3303415-B1 VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF ALCON INC (CH) 2022-12-28 EP disclosed
US-10324311-B2 Visible-light photoinitiators and uses thereof NOVARTIS AG (CH) 2019-06-18 US disclosed
EP-3303415-A1 VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF Novartis AG (CH) 2018-04-11 EP disclosed
WO-2016193912-A1 VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF NOVARTIS AG (CH) 2016-12-08 WO disclosed
US-20160357031-A1 VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF ALCON INC. (CH) 2016-12-08 US disclosed
CN-105601544-A Synthesis method of 2-methoxyl-5-amino sulfanoylmethyl benzoate SUZHOU CHENGHE PHARMACEUTICAL & CHEMICAL CO LTD 2016-05-25 CN disclosed
CN-105461549-A Synthesis technology of glibenclamide intermediate 5-chloro-2-methoxyben zoic acid TIANJIN PHARMACEUTICAL GROUP GENCOM PHARMACEUTICAL CO LTD 2016-04-06 CN disclosed
US-8476455-B2 1-N-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them LABORATOIRE THERAMEX (MC) 2013-07-02 US disclosed
US-20070112009-A1 1-N-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them LABORATOIRE THERAMEX (MC) 2007-05-17 US disclosed
EP-1694650-A1 1-N-PHENYL-AMINO-1H-IMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LABORATOIRE THERAMEX (MC) 2006-08-30 EP disclosed
WO-2005058842-A1 1-N-PHENYL-AMINO-1H-IMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LABORATOIRE THERAMEX (MC) 2005-06-30 WO disclosed
JP-2004244417-A METHODS FOR PRODUCING 5-FORMYL-2-METHOXYBENZOIC ACID AND ITS ESTER AND INTERMEDIATE FOR PRODUCING THE SAME KYORIN PHARMACEUT CO LTD 2004-09-02 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10324311-B2 Visible-light photoinitiators and uses thereof SIRT5, IK, IGLV6-57 MRGPRX4 4778/4885CFD 1765/4885TTR 1842/4885
US-20160357031-A1 VISIBLE-LIGHT PHOTOINITIATORS AND USES THEREOF SIRT5, IK, IGLV6-57 MRGPRX4 4778/4885CFD 1765/4885TTR 1842/4885
US-20070112009-A1 1-N-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them H1-0, H1-5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MRGPRX4 658/4885CFD 1838/4885TTR 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.